Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Inn The executives: A Remunerating Profession Decision for Energetic People- Mom finds out she has cancer after noticing something was off while breastfeeding
- The most effective method to Perceive the Early Side effects of Cellular breakdown in the lungs
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- The Way to Monetary Freedom: A Viable Aide
- Could the Star of Bethlehem have actually been a comet?
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- 37 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- 2024 Watch Gathering: The Best Watches of the Year
